MedTrace Logo

Whole Versus Partial Gland Boost During Prostate SBRT

NCT07574489 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 186

Last updated 2026-05-13

No results posted yet for this study

Summary

This phase 2/3 randomized trial evaluates whether dose escalation to the dominant intra-prostatic lesion (DIL) compared to whole gland dose escalation during prostate stereotactic body radiotherapy (SBRT) results in differences in genitourinary (GU) and gastrointestinal (GI) toxicities.

Conditions

Interventions

RADIATION

Prostate stereotactic body radiotherapy with whole gland boost

External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost

RADIATION

Prostate stereotactic body radiotherapy with DIL boost

External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost to the dominant intra-prostatic lesion.

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Michael Baine, MD, PhD · University of Nebraska medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-25
Primary Completion
2032-08-25
Completion
2035-08-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07574489 on ClinicalTrials.gov